CSF2 and Sepsis: In 2006, a double-blind, placebo-controlled RCT showed that low-dose GM-CSF (3 μg kg−1·d−1) reduced the antibacterial treatment duration, length of hospital stay, and infection-related complications in sepsis patients with abdominal infection (Orozco et al., 2006).